Online Impact
Statistics from Altmetric.com
ARTICLE USAGE
Cited By
Article Information
Volume 17, Issue 18, pp. 6097-6105
PubMed
Published By
Print ISSN
Online ISSN
History
- Received April 11, 2011
- Revision received June 27, 2011
- Accepted July 15, 2011
- Published first July 26, 2011.
Article Versions
- Previous version (July 26, 2011 - 12:28).
- You are viewing the most recent version of this article.
Copyright & Usage
©2011 American Association for Cancer Research.
Author Information
- Sahar A. Saddoughi1,2,
- Elizabeth Garrett-Mayer2,5,
- Uzair Chaudhary2,6,
- Paul E. O'Brien2,
- Larry B. Afrin2,
- Terry A. Day2,3,
- M. Boyd Gillespie2,3,
- Anand K. Sharma2,4,
- Christina S. Wilhoit2,
- Robin Bostick2,
- Can E. Senkal1,2,
- Yusuf A. Hannun1,2,
- Jacek Bielawski1,2,
- George R. Simon2,6,
- Keisuke Shirai2,6, and
- Besim Ogretmen1,2
- Authors' Affiliations: 1Department of Biochemistry and Molecular Biology; 2Hollings Cancer Center; 3Department of Otolaryngology and Head and Neck Surgery; 4Department of Radiation Oncology; 5Department of Medicine, Division of Biostatistics and Epidemiology; and 6Department of Medicine, Division of Hematology and Oncology, Medical University of South Carolina, Charleston, South Carolina
- Corresponding Author:
Besim Ogretmen or Keisuke Shirai, Hollings Cancer Center, Medical University of South Carolina, 86 Jonathan Lucas Street, Charleston, SC 29425. Phone: 843-792-0940; Fax: 832-792-2556; E-mail: ogretmen{at}musc.edu or shirai{at}musc.edu
September 2011
Volume 17, Issue 18
Volume 17, Issue 18
Results of a Phase II Trial of Gemcitabine Plus Doxorubicin in Patients with Recurrent Head and Neck Cancers: Serum C18-Ceramide as a Novel Biomarker for Monitoring Response
Jump to section
Advertisement